Novartis unveils a new strategic plan around the United States and eight drug brands

ZURICH, Sept 22 (Reuters) – Novartis on Thursday announced a new strategic plan aimed at making U.S. growth a top priority and focusing on eight drug brands the company says could drive sales of the order of several billion dollars.

At an event for investors, the Swiss pharmaceutical group said it would increase the share of American patients in clinical trials, and offer American employees better prospects for advancement within the company. the company.

The aspiration of Novartis, ranked 10th in the US market, is to “organically grow its US business to become a top player by 2027”.

The group added that it aims to become one of the top three players in China, while maintaining top positions in Germany and Japan.

The US president last month signed a plan to support households in the face of rising prices, which notably authorizes the government to negotiate the prices of certain prescription drugs and to cap the costs of the public health program Medicare.

“Regarding the price cap, although it is a challenge, we believe it is manageable and (we are) not making any change in our direction,” Vas Narasimhan said. , CEO of Novartis, at the event.

Novartis also announced a strategy based on eight major drug brands, following the decision to spin off from Sandoz, to focus more on patented prescription drugs.

According to the laboratory, the brands Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix have the potential for maximum sales of several billion dollars.

The official also confirmed Novartis’ previously announced financial targets. (Report Ludwig Burger and John Revill; French version Alizée Degorce, edited by Kate Entringer)

Source link -91